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Summary  
Sorafenib has been evaluated in several phase II and III studies in patients with locally 
advanced/metastatic radioactive iodine (RAI)-refractory DTC, reporting partial responses, 
stabilization of the disease, and improvement of progression free survival. Best responses were 
observed in lung metastases, and minimal in bone lesions. On the basis of these studies sorafenib 
was approved for the treatment of metastatic differentiated thyroid carcinoma in November 2013. 
Few studies suggested that reduction of Tg levels, or of average SUV at the FDG-PET, could be 
helpful for the identification of responding patients; but further studies are needed to confirm these 
results. Tumor genetic marker levels did not have any prognostic or predictive role in DTC patients. 
Commonest adverse events include skin toxicity, gastrointestinal and constitutional symptoms.  
Encouraging results have been also observed in patients with MTC. Many studies are ongoing to 
evaluate long term efficacy and tolerability of sorafenib in DTC patients.  
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Thyroid cancer (TC) represents the predominant endocrine malignancy (7th most common cause of 
new cancer in the US for women (in 2007); 14th in men). The incidence of papillary thyroid cancer 
(PTC) is increasing in the last decades [1-4]. 
The reasons of this increasing incidence are not clear. The wide use of neck ultrasonography and 
fine needle aspiration (FNA) of thyroid nodules is partially related to an increasing diagnosis of 
small TC. Among risk factors for TC, ionizing radiations play an important role, in particular 
considering exposure in the early life (about 2-4% of the subjects exposed to radiation during 
childhood or adolescence show TC) [5]. The exposure to nuclear explosions or nuclear accidents 
constitutes a risk factor for TC [6]. In fact, the incidence of TC rapidly increased in childhood, after 
the nuclear accident of Chenobyl (in 1986), in the regions of Belarus and Ukraine, exposed to the 
radiation fallout [7]. Even low doses of radiation exposure might lead to the onset of thyroid 
nodules and cancer [8]. Iodine deficiency has been suggested to be associated with a higher 
frequency of follicular thyroid cancer (FTC) [9]. Recently, also autoimmune thyroiditis has been 
shown to be a risk factor for PTCs [10, 11]. Furthermore, new risk factors are emerging in the last 
decades [12]. 
While the incidence of TC is increasing in the last decades, the prevalence of TC deaths per year (in 
relation to the number of new cases) is decreased from 15% to 5% [13].  
Differentiated thyroid carcinomas (DTC) that arise from follicular cells account for more than 90% 
of all thyroid tumors, and are subdivided into PTC or FTC according to histopathological criteria. 
Medullary thyroid cancer (MTC) accounts for < 5% of TC [1].  
Completion total thyroidectomy is the treatment of choice for PTCs and FTCs [14].  
Radioiodine is not routinely recommended in low risk DTC patients, and it should be considered in 
intermediate risk (IR), and it is routinely recommended in high-risk (HR) patients [15, 16]. 
After surgery (and eventually radioiodine) patients with PTC and FTC are followed by the 
determination of basal or thyroid-stimulating hormone (TSH)-stimulated thyroglobulin (Tg), and by 
 4 
neck ultrasonography [17-19].  
More than 90% of patients with DTC has a normal life expectancy [20]. Only about 5% of DTC 
patients have distant metastasis at the diagnosis (in the lungs, or bones, or other sites). However, 
during the follow-up about 10%–15% of patients have recurrent disease (in the thyroid bed, or 
lymph nodes), with a survival reduction (from 70% to 50%, at 10-year) [21, 22].  
During tumor progression, DTC cancer cells may lose the iodide uptake ability, and TC changes 
into resistant to radioiodine, while prognosis significantly worsens [20-22].  
Radiotherapy is of limited efficacy in the treatment of dedifferentiated thyroid cancer [23]. The only 
approved chemotherapy in most countries is doxorubicin, but partial or complete responses are rare 
and the toxicity profile is not favorable.  
 
1.1 Molecular pathways involved in DTC progression 
During the last decades, several somatic mutations in different molecular pathways in TC have been 
shown, and associated with its development and progression.  
Activating RET (REarranged during Transfection) mutations and rearrangements have been 
identified in various human cancers [24]. RET is a proto-oncogene located on 10q11.2, encoding a 
transmembrane protein harboring a tyrosine kinase (TK) at the intracellular region. In 
approximately 40% of adult sporadic PTC, RET/PTC rearrangements are present [25].	  The most 
frequent rearrangements are RET/PTC1, and RET/PTC3. RET/PTC rearrangements are frequently 
found in microcarcinomas and in benign thyroid lesions, so it has been hypothesized that RET/PTC 
rearrangements are	  determinant for the tumor initiation, but not for its progression [26-29].  
The serine-threonine kinase BRAF is a member of the RAF family proteins. A substitution from 
valine to glutamate at residue 600 (V600E) of BRAF is present approximately in 45% of PTC, and 
it has been correlated with the tumor aggressiveness, and the loss of iodide uptake [25]. 
Recently mutations in the promoter of the telomerase reverse transcriptase (TERT) gene have been 
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found in 11% PTCs, 11% of FTCs, 37% of poorly differentiated thyroid cancers (PDTC), and 42% 
of ATCs. These studies first showed that TERT promoter mutations in TCs are particularly 
prevalent in the aggressive TCs, overall in presence of BRAF mutations [30, 31].  
K-RAS, N-RAS and H-RAS belong to the RAS (from “Rat Sarcoma”) gene family, encoding 
intracellular G-proteins involved in activation of different intracellular signaling pathways. RAS 
mutations occur in ~10% of PTCs, and in about 40-50% of FTCs. The association between RAS 
mutations and a more aggressive behaviour of TC has been shown [32].  
About 30-40% of FTC show PAX8/PPARγ rearrangements, as 2-10% of follicular adenomas; these 
rearrangements are less common in the follicular variant of PTC [25]. 
TCs are more vascularized than normal thyroid tissue, and there is a unambigouous correlation 
between increased angiogenesis and a more aggressive TC behavior [33].  
The expression of angiogenesis stimulators and inhibitors in TC is associated with clinical features 
of the disease [34]. 
Some of these are Vascular Endothelial Growth Factor (VEGF)/VEGF receptor (VEGFR), 
Epidermal Growth Factor (EGF)/EGFR, platelet-derived growth-factor (PDGF)/PDGFR, fibroblast 
growth factor (FGF)/FGFR, and hepatocyte growth factor (HGF)/c-Met.  
VEGF is overexpressed and its main receptor VEGFR-2 is generally upregulated in DTC	  [35] and it 
is involved in neoplastic growth, progression and aggressiveness. Systemic administration of 
antiangiogenic drugs that target VEGF pathway has become a therapeutic option for TC patients 
[36].  
It has been suggested that EGFR is highly expressed in aggressive PTC with lymph node 
metastasis, and plays a role in the progression of TC [37], but these results are in contrast  with 
findings from other studies [38].  
 
1.2 Molecular pathways in MTC 
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Most cases of MTC (originating from the cells producing calcitonin) are sporadic, while about 20% 
of MTC cases belong to a multiple endocrine neoplasia syndrome type 2 (MEN2). MTC is a slow 
growing cancer, even if the 10-year overall survival rate is 40–50% in the presence of metastatic 
disease. Surgery is the only curative modality available [39], and no effective therapies exist for 
metastatic MTC, as it is not responsive to external radiotherapy, radionuclide therapy, or 
chemotherapy. 
Activating point mutations in RET are associated with the hereditary cancer syndromes. There are 
three subtypes: MEN2A, MEN2B, and familial medullary thyroid carcinoma. There is a marked 
correlation between the position of the RET point mutation and the phenotype of MTC.  
Almost all hereditary cases of MTC and 30–50% of the sporadic ones show activating RET 
mutations [40], so RET is considered an important therapeutic target for MTC [41]. 
Also other genetic events are determinant for the pathogenesis of MTC, as indicated by the recent 
findings of H-RAS mutations in 13-56% of RET-negative sporadic MTC and the activation of the 




2. Tyrosine Kinase Inhibitors (TKIs) 
Many strategies have been developed to block TKs. 
TKIs are generally small organic compounds that compete with the ATP-binding site of the 
catalytic domain of the TKs [45], inhibiting TK autophosphorylation and activation, and preventing 
intracellular signaling pathways activation. TKIs can be specific to one or several TKs; so, a single 
TKI may target multiple TKs [46]. Most TKIs are multikinase inhibitors, being not specific for one 
particular type of TK. Various TKIs have been evaluated in TC, in vitro, and in pre-clinical, and 
clinical studies.  
TKI blockade may be achieved also through monoclonal antibodies against growth factors 
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receptors.  
TKIs act on the above mentioned pathways involved in angiogenesis, growth, invasiveness, and 
local and distant spread [47].  
TKIs are emerging as effective therapies of aggressive TC. Since TKIs act on pathways that are not 
selective for a specific type of TC, they have been evaluated in various tumors, including DTC, 
MTC and ATC [48].  
The Response Evaluation Criteria in Solid Tumors (RECIST) estimate the individual patient 
response considering the clinical trials evaluating TKIs [49]. 
 
3. Sorafenib  
Sorafenib (Nexavar®) is a small molecular (a bi-aryl urea) multi-targeted TKI, approved for the 
treatment of primary kidney cancer [advanced renal cell carcinoma (RCC)] and advanced primary 
liver cancer [hepatocellular carcinoma (HCC)].  
It demonstrated inhibitor activity against VEGFR-2 and 3, c-Kit, PDGFR, RET/PTC, and Raf 
kinases (more avidly C-Raf than B-Raf), and it is able to target the Raf/Mek/Erk pathway (MAPK 
pathway). In addition, sorafenib has been also shown to induce apoptosis through down-regulation 
of Mcl-1 in many cancer types [50, 51].  
Sorafenib is approved in USA and UE for the treatment of RCC [51], and HCC [51]. Sorafenib has 
been also approved for the treatment of metastatic DTC in November 2013 [52].  
 
3.1 Pharmacokinetic (PK) Profile 
3.1.1 Absorption and distribution 
The mean relative bioavailability of sorafenib tablets after their administration is 38–49% in 
comparison with an oral solution. The absolute bioavailability is still not clear. Upon oral 
administration, sorafenib reaches peak plasma concentrations in about 3 hours. The absorption of 
sorafenib decreased of about 30% if it is administered with a high-fat meal with respect of the 
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administration in the fasted state. Mean C-max and area under curve increased less than 
proportionally beyond doses of 400 mg bid. Sorafenib binds human plasma proteins in vitro with a 
probability of 99.5%. 
Multiple dosing of sorafenib for 7 days resulted in a 2.5- to 7-fold accumulation with respect to 
single dose administration. Steady state plasma sorafenib concentrations are achieved within 7 days, 
with a peak to trough ratio of mean concentrations < 2 [51]. 
 
3.1.2 Biotransformation and elimination 
Sorafenib is metabolized mainly in the liver and goes through oxidative metabolism, mediated by 
cytochrome P450 3A4 (CYP3A4), and glucuronidation by UGT1A9. Its elimination half-life is 
about 25–48 hours. Bacterial glucuronidases cleave sorafenib conjugates in the gastrointestinal 
tract, permitting the reabsorption of the unconjugated drug. Considering an oral administration of 
100 mg of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 
77% of it excreted in faeces, and 19% in urine as glucuronidated metabolites. The 51% of the dose 
accounts for unchanged sorafenib; it was excreted in faeces but not in urine, suggesting that biliary 
excretion of unchanged drug might contribute to the elimination of sorafenib. 
Sorafenib accounts for approximately 70–85% of the circulating analytes in plasma at steady state. 
Eight metabolites of sorafenib are known, among which five have been revealed in plasma, and the 
main one is the pyridine N-oxide, showing in vitro potency similar to that of sorafenib. This 
metabolite represents about 9-16% of circulating analytes at steady state. 
Neither age nor gender and race influence sorafenib PK. 
Subjects with normal renal function, mild, moderate or severe renal impairment, do not show any 
relationship between sorafenib exposure and renal function. 
The PK of sorafenib in Child-Pugh A and B non-HCC patients were similar to the PK in healthy 
volunteers, and no data are available for Child-Pugh C (severe) hepatic impairment. Sorafenib is 
primarily excreted through the liver, and exposure can be increased in this patient population [51].  
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3.1.3 Drugs interactions 
Sorafenib is metabolized by CYP3A4 such as sunitinib, pazopanib and vandetanib and it seems to 
be the more susceptible to CYP3A4 inducers or inhibitors. 
CYP2B6, CYP2C8 and CYP2C9 are inhibited in vitro by sorafenib with almost the same potency. 
In clinical PK studies, the concurrent administration of sorafenib 400 mg bid with the CYP2B6 
substrate cyclophosphamide, or paclitaxel, a CYP2C8 substrate, did not show a clinically 
meaningful inhibition. For this reason, sorafenib at the recommended dose of 400 mg bid could not 
be an in vivo inhibitor of CYP2B6 or CYP2C8. 
Moreover, the concurrent administration of sorafenib and the CYP2C9 substrate warfarin did not 
evidence changes in mean prothrombin time-international normalized ratio with respect to placebo. 
For this reason, the risk for a clinically relevant in vivo inhibition of CYP2C9 by sorafenib could be 
low. However, patients treated with warfarin or phenprocoumon should have their international 
normalized ratio checked regularly. 
The concurrent treatment with sorafenib and midazolam, dextromethorphan or omeprazole 
(substrates for cytochromes CYP3A4, CYP2D6 and CYP2C19, respectively) did not alter their 
exposure, suggesting sorafenib is neither an inhibitor nor an inducer of these cytochrome P450 
isoenzymes. For this reason, clinical PK interactions of sorafenib with these substrates are 
uncommon. 
As already described above, although sorafenib is metabolized by CYP3A4, which can be inhibited 
or induced by various other drugs and environmental chemicals, more than half of the elimination 
of the drug is represented by biliary excretion of the unchanged parent drug, and this kind of 
elimination is not affected by agents inhibiting CYP3A4 activity. A paper evaluating the concurrent 
treatment with the CYP3A4 inhibitor ketoconazole and sorafenib in healthy male subjects did not 
evidence any change in the sorafenib PK. 
The metabolism of sorafenib can be increased by strong CYP3A4 inducers, but this possible 
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interaction has not been assessed by clinical studies [51]. 
Recently, it was demonstrated a synergistic anti-proliferative effect of metformin and sorafenib: the 
addition of metformin enabled a significative reduction of sorafenib dose without loss of its growth 
inhibitory efficacy. This treatment could be used to reduce dose-related toxic side-effects [53].  
 
3.1.4 Protein p-glycoprotein-substrates 
Sorafenib is able to inhibit the transport protein p-glycoprotein (P-gp) in vitro. Increased plasma 
concentrations of P-gp substrates such as digoxin cannot be excluded with the concurrent treatment 
with sorafenib. In vitro, the glucuronidation is inhibited by sorafenib through UGT1A1 and 
UGT1A9 [51]. 
The clinical significance of this inhibition is not completely known and drugs that are metabolized 
by these enzymes should be used with caution in patients treated with sorafenib owing to a potential 
risk of drug interactions. 
Sorafenib has a moderate affinity for several members of the ATP-binding cassette sub-family 
(ABC). 
In LLC-PK1, Caco-2, K562, and MDCKII cells, it was shown that sorafenib is a moderate substrate 
for the efflux transporter ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) 
[54]. 
It has been shown in vivo that sorafenib is a substrate of ABCG2 and probably also of ABCB1. 
Mice completely lacking both functional above mentioned transporters and administered with oral 
sorafenib had a higher accumulation of this drug in the brain than mice lacking either of the 
transporters alone. 
 
3.1.5 Combination with other anti-neoplastic agents  
Sorafenib has been administered with other anti-neoplastic agents in clinical studies, including 
gemcitabine, cisplatin, oxaliplatin, paclitaxel, carboplatin, capecitabine, doxorubicin, irinotecan, 
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docetaxel and cyclophosphamide, demonstrating no clinically relevant effect on the PK of 
gemcitabine, cisplatin, oxaliplatin or cyclophosphamide. 
No evident drug interactions between sorafenib and carboplatin, dacarbazine, gemcitabine, 
oxaliplatin, and paclitaxel was observed in phase I clinical trials. However, the doxorubicin area 
under curve was 47% greater upon co-administration with sorafenib, even if no significant 
difference in toxicity was observed in spite of the greater exposure to doxorubicin. If 
coadministered with irinotecan, exposure was greater for both irinotecan (26%–42%) and its active 
metabolite SN-38 (70%–120%), but the diarrhea resulting from irinotecan did not present an 
appreciable worsening with the combination [51]. 
 
3.1.6 Sorafenib and other targeted agents 
A phase I dose-escalation trial of sorafenib and bevacizumab was performed on 39 patients with 
various cancers at below-recommended single-agent doses [55]. This combination showed 
promising clinical activity in particular in ovarian cancer, but the rapidity and frequency of dose 
reductions indicated that long-term dosage was not tolerated, and the need for alternative dosing 
schedules.  
The intermittent sorafenib dosing with bevacizumab has been evaluated by a phase I study and 
evidenced a clinical activity; a few patients required a sorafenib dose reduction and showed few 
side effects [56]. 
The combination of sorafenib with erlotinib was investigated in a phase I trial: it was well tolerated 
and showed promising activity [57]. In a phase II trial for the combination, a higher progression-
free survival (PFS) and OS was seen in the EGFR wild type and the EGFR FISH-negative patients 
with advanced non-small cell lung cancer, compared to erlotinib alone [58]. However, the benefit of 
this combination needs to be confirmed by additional researches. A pre-clinical study on the 
combination of sorafenib with erlotinib or cetuximab has shown synergistic antitumor activity in 
both colorectal cancer and non-small cell lung cancer [59].  
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A phase I study evaluated sorafenib plus interferon (IFN)-α-2a in advanced RCC and melanoma 
and it evidenced preliminary antitumor activity and it was well-tolerated [60]. Another study was 
conducted on the combination of sorafenib and IFN-α-2b in advanced RCC patients and it showed 
substantial activity, but the toxicity was higher than the one of either drug alone [61]. However, 
dose reductions and breaks between cycles allowed for long term therapy. On the contrary, more 
recently, a phase II study, evaluating the combination of sorafenib and pegylated IFN-α-2b in 
metastatic melanoma patients, evidenced a modest clinical activity and severe side effects, such as 
fatal bleeding complications [62].  
However, the combination of sorafenib with other different targeted agents could be associated with 
important adverse events (AEs).  In  fact, it has been reported a case of fatal heart failure after a 26-
months combination of two TKIs (sorafenib and imatinib) in a patient treated due to chronic 
myeloid leukemia and PTC [63].  
 
3.2 Sorafenib in TC in vitro studies 
Carlomagno et al. [64] first showed that sorafenib is capable of inhibiting oncogenic RET mutants, 
demonstrating that it prevented the growth of the TPC1 and TT, thyroid carcinoma cell lines, with 
the RET/PTC1 and C634W RET mutation, respectively. 
These results were subsequently confirmed in the PTC cells carrying the RET/PTC1 rearrangement, 
that resulted more sensitive to sorafenib with respect to PTC cells carrying BRAF mutation [65]. 
More recently it has been shown that sorafenib had important effects on cell proliferation, cell cycle 
arrest, and signal transduction pathways in PTC cells harboring RET/PTC1 rearrangement, and that 
it could be potentially used to enhance the expression of iodide-handling genes and to inhibit the 
expression of glucose transporter genes [50]. 
Sorafenib exerted antineoplastic activity in the other human MTC cell line (MZ-CRC-1), too [66].  
Moreover, it has been also demonstrated that sorafenib has antineoplastic action in vitro, and 
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inhibits the angiogenesis and growth of orthotopic xenografts of ATC in nude mice [67]. 
This drug, therefore, potentially may inhibit TC growth via anti-proliferative and anti-angiogenic 
mechanisms. 
 
4. Sorafenib clinical studies  
4.1 Phase II studies (Table I) 
A phase II trial, published in 2008, assessed the efficacy of sorafenib in 30 patients with metastatic, 
iodine-non-avid, TC, including DTC, PDTC, MTC, and ATC subtypes. The drug was administered 
at 400 mg bid; the median duration of treatment was 27 weeks. Six patients (20%) discontinued 
treatment owing to AEs. Doses were reduced in 47% of patients (14 patients) to control toxicities. 
A partial response (PR) rate was observed in 23.3% and a stable disease (SD) rate in 53.3%, with a 
clinical benefit rate (partial response + stable disease) of 77%, and a median progression-free 
survival (PFS) of 21 months [68]. 
Few months later it was published a study in 58 patients with metastatic TC (25 chemotherapy 
naive patients with metastatic PTC; 33 patients with metastatic PTC previously treated with 
chemotherapy, or other subtype as Hurthle cell, Follicular, ATC, or mixed TC). Patients were 
treated with sorafenib at 800 mg daily (in two doses; generally well tolerated). It was demonstrated 
that sorafenib has clinical antitumor activity in metastatic TC, as a PR was observed in 6 patients, 
while 23 patients had SD longer than 6 months [69]. 
A prospective phase II study assessed the efficacy of sorafenib in reinducing radioactive iodine 
(RAI) uptake in patients with progressive metastatic or locally advanced RAI refractory DTC. 
Thirtyone patients received sorafenib 400 mg twice daily, for 36 weeks: 25% had a PR and 34% a 
SD, the estimated PFS was 58 weeks. However, 22% of patients had progressive disease and 
diagnostic whole body scan did not evidence any reinduction of RAI uptake. The efficacy of 
sorafenib was lower in patients with bone metastases [70]. 
Brose et al. published another open-label phase II study of sorafenib at maximum dose (800 mg 
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daily) in metastatic iodine-refractory TC, in 55 patients with different histological subtypes (47% 
PTC, 36% FTC/Hürthle Cell, 8% MTC, 9% PDTC/ATC). Genotyping of BRAF was complete in 
16 patients. PFS increased in PTC patients with B-RafV600E, with respect to wild-type B-Raf (84 
versus 54 weeks, P=0.028) [71]. A paper published in 2010 reports the M. D. Anderson Cancer 
Center’s experience with the off-label use of TKs inhibitors sorafenib and sunitinib for refractory to 
iodine DTC (PTC and FTC). Sorafenib was used in 13 patients, at the same dose of the previous 
reported trials. The obtained data were similar to those of other phase II studies evaluating sorafenib 
in TC (remission rate of 20%, durable response rate of 66%, and a clinical benefit rate of 80%; PFS 
was 19 months, and the median overall survival at 2 years was 67%). A response variability to 
sorafenib of the different metastases in the same patient was observed, with the best response in 
lung, and minimal in non-irradiated bone lesions, suggesting a differential expressions and 
inhibitions of various receptors. After the therapy, Tg levels were reduced, and a correlation 
between the log Tg and the response to the treatment was demonstrated (the reduction preceded 
tumor shrinkage), suggesting that Tg would be a good biologic marker of response to therapy [72]. 
Another phase II study was conducted in 19 patients with metastatic MTC and 15 patients with 
locally advanced radioiodine refractory DTC. The radiological response rate (RR) was 18% for 
patients with DTC, while the PFS at 2 years was 62% and OS 72%. However, 79% of patients 
required dose reduction for AE (hand–foot syndrome, other skin toxicities, diarrhoea and alopecia). 
A patient who had demonstrated a dramatic response after 3 months of therapy showed a mutation 
in BRAF exon 15 [73]. 
In the 2011 ASCO annual meeting, the results of UPCC 03305 phase II trial of sorafenib for 
advanced thyroid carcinoma were presented. Fifty-five patients (85% DTC/PD, 9% ATC, 6% 
MTC) received the drug at same dose provided in preceding studies. A longer PFS was observed in 
patients with DTC/PD (96 weeks versus 93.6 weeks) (38% achieved a PR, 47% had SD) [74].  
Capdevila et al. conducted a retrospective analysis of patients with metastatic TC treated with 
sorafenib in seven Spanish referral centers. Thirthy-four patients were included between June 2006 
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and January 2010. They were all not suitable for any traditional therapies and received 400 mg 
twice a day sorafenib. Sixteen patients presented DTC (7 papillary, 9 follicular), 15 MTC, and 3 
ATC. Eleven patients (32%) achieved PR and 14 (41%) had SD beyond 6 months. RRs were 47% 
(7 of 15) for MTC, 19% (3 of 16) for DTC and 33% (1 of 3) for ATC. With a median follow-up of 
11.5 months, mPFS were 13.5, 10.5 and 4.4 months for DTC, MTC and ATC respectively. A 
significant decrease in tumor markers (Tg, calcitonin and carcinoembryogenic antigen) was also 
observed [75]. 
Another phase II trial of sorafenib (400 mg bid) was conducted in 31 patients with advanced radio-
iodine refractory DTC; the median follow-up and period of treatment was 25 and 9 months, 
respectively. Among the mutations found, BRAF V600E was the most present, but it was not 
related to disease progression. PR was seen in 31% of patients and 45% achieved SD after a median 
follow-up of 25 months. The dose of TKI used was generally well tolerated, although dose 
reductions were required in 58% of patients [76].  
Savvides et al. treated 20 ATC patients with sorafenib 400 mg bid. Two of them had a PR (10%) 
and an additional 5 of 20 (25%) had SD. The duration of response (in the two responders) was 10 
and 27 months, respectively. The median duration in SD was 4 months (range 3–11 months). The 
overall mPFS was 1.9 months (with a median and 1-year survival, of 3.9 months, and 20%, 
respectively). Toxicity was manageable as previously described, including hypertension and skin 
rash [77]. 
Recently, the results obtained in a retrospective, longitudinal study on use of sorafenib in patients 
with progressive RAI-refractory DTC were published (sorafenib has been used off-label in 17 
patients, at conventional dose). Thirty% of patients achieved PR, 41% SD and 18% PD, median 
PFS was 9 months and median OS 10 months. The drug was tolerated (however 5 fatal events were 
reported: 3 severe bleeding, 2 cardiac arrest), but all patients needed dose reductions and/or 
transient drug interruption to control AEs. These severe AEs have been attributed to the bad general 
conditions of the patients at the beginning of the trial (worse than in previous studies). The 
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radiological response was greater in lymph nodes, than in lung metastasis. An early reduction in 
average SUV (Standardized Uptake Value) was recorded in all patients, but it was greater in 
responding subjects, suggesting that the FDG-PET (Fluorodeoxyglucose – Positron Emission 
Tomography) could be helpful for the timely identification of non-responding patients [78]. 
The role of sorafenib in the treatment of progressive metastatic DTC was subsequently confirmed 
by other studies, too [79]. 
Benekli et al. analyzed the results of the treatment in 14 DTC (PTC number [n] =10; FTC n=4) and 
16 MTC. The median age was 57 years (range: 28-79 years), and there were 18 males and 12 
females. All DTC patients were iodine-refractory and had been previously treated with radioactive 
iodine (range: 1-7 doses). Sorafenib was used for a median of 12 months (range: 1-49 months). The 
overall response rate was 20%, all PRs (no complete response). The overall response rate was 14% 
in DTC and 25% in MTC patients. The median PFS was 17.1 months (95% confidence interval 
[CI]: 7.3-26.8). The 2-year PFS and OS were 39% and 68%, respectively. DTC and MTC patients 
had similar survival outcomes: median PFS of 21.3 months (95% CI: 5.8-36.7) versus 14.5 months 
(95% CI: 3.7-25.2), respectively (P=0.36) (with the median OS not reached in either group). Tumor 
marker levels did not have any prognostic or predictive role. The sorafenib toxicity profile was 
similar to that of other trials [80]. 
Twenty patients with advanced RAI-refractory thyroid carcinoma were enrolled (March 2011-
March 2014) by Gallo et al. (sorafenib 400 mg bid, tapering the dose in case of side effects). CT 
scans were performed every 3-4 months. Five patients stopped sorafenib within 90 days due to 
severe toxicities. Median PFS was 248 days. Five patients had a PR (achieved in all cases within 3 
months), whereas 5 had SD at 12 months. Durable response rate (PR plus SD) for at least 6 months 
was 50 %, among those who received sorafenib for at least 3 months. Commonest AEs included 
skin toxicity, gastrointestinal and constitutional symptoms  [81]. 
 
4.2 Phase III studies 
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On the basis of the phase II trials results, it has been conducted a multicenter, double-blind 
randomized phase III study, that evaluated the efficacy and safety of sorafenib with respect to 
placebo, in locally advanced/metastatic RAI-refractory DTC. 
The DECISION trial was designed to evaluate the capability of sorafenib to improve PFS in 
patients with locally advanced or metastatic, RAI-refractory DTC (defined as a target lesion with no 
iodine uptake on a post RAI scan performed under conditions of a low iodine diet and adequate 
TSH elevation or recombinant human TSH stimulation). Efficacy and safety of sorafenib have been 
assessed every 56 days (two cycles) and 28 days (1 cycle) for the first 8 months and every 56 days 
after, respectively. 
Patients have been randomized 1:1 to receive placebo or sorafenib. The inclusion criteria were: age 
>18, life expectancy of at least 12 weeks, locally advanced or metastatic DTC (PTC, FTC, Hurtle 
cell or PDTC) with at least one measurable lesion (measured by computer tomography or magnetic 
resonance imaging) and disease progression within 14 months. Some patients who have had some 
iodine uptake have been also included in the study. 
Other inclusion criteria were: a performance status < 2 according to Eastern Cooperative Oncology 
Group, adequate TSH suppression (<0.5 mU/L), absence of renal ad liver failure and adequate bone 
marrow function. Patients who had yet received any treatment with TKI, monoclonal antibodies 
against VEGFRs or other targeted agents, cytotoxic chemotherapy or thalidomide, were excluded. 
The initial group comprises a population of 417 patients (207 treated with sorafenib and 210 with 
placebo), while the final group was constituted by 416 patients (207 treated with sorafenib and 209 
with placebo). Median PFS was significantly higher in patients belonging to the sorafenib group 
(10.8 months) than in the placebo group (5.8 months). PFS improved in all pre-specified clinical 
and genetic biomarker subgroups, independently from mutation status [82]. 
Another phase III trial, conducted by Bayer, involving 417 patients, is still during [83]. 
 
5. Safety and tolerability  
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The most common AEs were: rash, alopecia and hand-foot syndrome, diarrhea; while the most 
important serious adverse reactions were: hypertension/hypertensive crisis, haemorrhage, 
myocardial infarction/ischaemia, gastrointestinal perforation, hepatitis. 
Fatal events were also reported (bleeding, cardiac arrest) in few patients (attributed to the bad 
general conditions of the patients).  
Undesirable effects are presented in the Table II. 
 
6. Limits and drug resistance 
The efficacy of sorafenib in DTC patients, even if promising, has given contrasting evidences in 
different clinical trials, probably owing to the drug resistance, that could arise from the activation of 
alternate mitogenic signals [84]. 
Sorafenib stops tumor growth, but does not remove tumor cells. Hence, the combination with other 
drugs, or with different TKIs has been recently proposed. 
The co-administration of sorafenib with different anti-neoplastic agents at their commonly used 
dosing regimens, showed any clinically relevant effect on the PK of gemcitabine, cisplatin, 
oxaliplatin or cyclophosphamide. 
In phase I clinical trials, dacarbazine, gemcitabine, oxaliplatin, doxorubicin and paclitaxel were 
administered with sorafenib without detectable drug interactions [85].  
The combination of bevacizumab and sorafenib  has been also reported (see 3.1.6 ) [55, 56], such as 
the combination of sorafenib with erlotinib (see 3.1.6 ) [57-59]. 
More recently, the combination of sorafenib with belinostat or panobinostat was studied in vitro in 
TC cells in vitro, showing no significant synergistic effect [86]. 
Attempts have been made to personalize the sorafenib therapy in each patient with DTC, on the 
basis of the molecular characterization of the tumor and of the host factors. Tumor genetic marker 
levels have not shown any prognostic or predictive role about sorafenib therapy in DTC patients. 
The possibility to test the sensitivity of primary TC cells from each subject to sorafenib, or  other 
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different TKIs,  might ameliorate the effectiveness of the treatment [87, 88]. 
Disease orientated in vitro drug screening, using primary human cancer cells, has predictive value 
for the clinical response activity [89, 90], and could prevent the administration of inactive drugs 
(potentially dangerous) to patients [91]. In fact, a positive (in vitro) chemosensitivity test permits to 
predict in vivo effectiveness in 60% of cases [92], while a negative chemosensitivity test (in vitro) is 
associated with a 90% of ineffectiveness of the chemotherapy in vivo [89]. 
Till now, primary TC cell cultures have been established only from surgical biopsies performed for 
therapeutic or diagnostic procedures. More recently, it has been demonstrated the possibility to 
obtain primary TC cell culture from FNA samples of ATC (FNA-ANA), overcoming surgical 
procedures, and opening the way to the use of FNA-ANA cells to test the sensitivity to different 
chemotherapeutics in each patient [56, 92-94]. 
 
7. Conclusion 
Sorafenib has been evaluated in several phase II and III studies in patients with locally 
advanced/metastatic RAI-refractory DTC, reporting PRs, stabilization of the disease, and 
improvement of PFS. Until now it has not yet been demonstrated an improvement of overall 
survival. On the basis of these studies sorafenib in November 2013 was approved for the treatment 
of metastatic DTC [52]. A response variability of the different metastases in the same patient to 
sorafenib was observed in several studies, with best response in lung, and minimal in bone lesions. 
Few studies suggested that reduction of Tg levels, or of average SUV at the FDG-PET, could be 
helpful for the timely identification of responding patients; but further studies are needed to confirm 
these results. Tumor genetic marker levels did not have any prognostic or predictive role in DTC 
patients. Commonest AEs include skin toxicity, gastrointestinal and constitutional symptoms. 
Andecdotal studies continue to report positive results of sorafenib in DTC [95]. 
Encouraging results have been also observed in patients with MTC, reporting PRs, stabilization  of 
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the disease, improvement of PFS, and reduction of circulating markers such as calcitonin and CEA. 
However, further studies are needed to evaluate sorafenib in MTC. 
Many studies are ongoing to evaluate long-term efficacy and tolerability of sorafenib in TC patients. 
However, further studies will be necessary to personalize the sorafenib therapy in each TC patient, 
on the basis of the molecular characterization of the tumor and of the host factors, to improve 
survival and the quality of life. 
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8. Expert commentary 
Sorafenib is active in patients with locally advanced/metastatic radioactive iodine (RAI)-refractory 
DTC, reporting PRs, stabilization of the disease, and improvement of PFS, and it is approved for the 
treatment of metastatic DTC. A response variability of the different metastases in the same patient 
to sorafenib was observed in different studies, with best response in lung, and minimal in bone 
lesions. Few studies suggested that reduction of Tg levels, or of average SUV at the FDG-PET, 
could be helpful for the timely identification of responding patients; but further studies are needed 
to confirm these results. Tumor genetic marker levels did not have any prognostic or predictive role 
in DTC patients. Commonest adverse events include skin toxicity, gastrointestinal and 
constitutional symptoms. Many studies are ongoing to evaluate long term efficacy and tolerability 
of sorafenib in DTC patients. 
The treatment with sorafenib in DTC patients might lead to drug resistance, that could arise from 
the activation of alternate mitogenic signals. Hence, the combination with other drugs, or with 
different TKIs has been recently proposed. 
Attempts have been made to personalize the sorafenib therapy in each patient with DTC, on the 
basis of the molecular characterization of the tumor and of the host factors, to improve survival and 
quality of life. 
Promising results have been also observed in patients with MTC, reporting PRs, stabilization  of the 
disease, improvement of PFS. However, further studies are needed to evaluate sorafenib in MTC. 
 
9. Five years view 
Many studies are ongoing to evaluate long-term efficacy and tolerability of sorafenib in DTC 
patients. These long term studies might finally clarify if sorafenib is able to prolonge OS in DTC 
patients. 
Future studies will evaluate results about sorafenib in patients with MTC.  
Other studies are evaluating the possibility to personalize the sorafenib therapy in each patient with 
 22 
DTC, on the basis of the molecular characterization of the tumor and of the host factors, to improve 
survival and quality of life. 
 
Key issues: 
1. Sorafenib (Nexavar®) is a small molecular (a bi-aryl urea) multi-targeted TKI, 
demonstrating inhibitor activity against VEGFR-2 and 3, c-Kit, PDGFR, RET/PTC, and Raf 
kinases (more avidly C-Raf than B-Raf), and it is able to target the Raf/Mek/Erk pathway 
(MAPK pathway). In addition, sorafenib has been also shown to induce apoptosis through 
down-regulation of Mcl-1 in many cancer types. 
2. Sorafenib was initially approved for the treatment of primary kidney cancer and advanced 
primary liver cancer. 
3. Sorafenib has been evaluated in several phase II and III studies in patients with locally 
advanced/metastatic radioactive iodine (RAI)-refractory DTC, reporting partial responses, 
stabilization  of the disease, and improvement of progression free survival.  
4. Best responses were observed in lymph node and lung metastases, and minimal in bone 
lesions.  
5. Commonest adverse events include skin toxicity, gastrointestinal and constitutional 
symptoms.   
6. Sorafenib was approved for the treatment of metastatic differentiated thyroid carcinoma in 
November 2013. 
7. Few studies suggested that reduction of Tg levels, or of average SUV at the FDG-PET, 
could be helpful for the identification of responding patients; but further studies are needed 
to confirm these results.  
8. Attempts have been made to personalize the sorafenib therapy in each patient with DTC, on 
the basis of the molecular characterization of the tumor and of the host factors. 
9. Promising results have been also observed in patients with MTC, reporting PRs, 
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stabilization  of the disease, improvement of PFS. 
10. The treatment with sorafenib in TC patients might lead to drug resistance, that could arise 
from the activation of alternate mitogenic signals. Hence, the combination with other drugs, 
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Responses	   Authors	  
PR	   SD	   PD	   PFS	  
(months)	  
Sorafenib	   30	  DeTC	   23.3%	   53%	   7%	   21	   Gupta-­‐Abramson	  et	  al.	  [68]	  Sorafenib	  	   41	  DeTC	   15%	   56%	   -­‐	   15	   Kloos	  et	  al.	  [69]	  Sorafenib	  	   31	  DeTC	   25%	   34%	   22%	   14.5	   Hoftijzer	  et	  al.	  [70]	  Sorafenib	  	   13	  DeTC	   20%	   60%	   20%	   19	   Cabanillas	  et	  al.	  [72]	  Sorafenib	   19	  DeTC	  15	  MTC	   21%	   65%	   14%	   	   Ahmed	  et	  al.	  [73]	  Sorafenib	   47	  DeTC	  5	  ATC	  3	  MTC	  
38%	  DeTC	   47%	  DeTC	   -­‐	   23.4	   Keefe	  et	  al.	  [74]	  
Sorafenib	   16	  DeTC	  15	  MTC	  3	  ATC	  
32%	  	   41%	   25%	  7%	  66%	  
13.5	  DeTC	  10.5	  MTC	  4.4	  ATC	  
Capdevila	  et	  al.	  [75]	  
Sorafenib	  	   31	  DeTC	   31%	   42%	   58%	   18	   Schneider	  et	  al.	  [76]	  Sorafenib	  	   20	  ATC	   10%	   25%	   -­‐	   1.9	   Savvides	  et	  al.	  [77]	  Sorafenib	  	   17	  DeTC	   30%	   41%	   18%	   9	   Marotta	  et	  al.	  [78]	  Sorafenib	  	  Sunitinib	  Vandetanib	  	  
32	  DeTC	  13	  ATC	  17	  MTC	  
15%	  vs	  8%	  DeTC	  36%	  MTC	  
-­‐	   -­‐	   6.7	  vs	  7	  DeTC	   Massicotte	  et	  al.	  [79]	  
 35 
Sorafenib	   14	  DeTC	  16	  MTC	   20%	   33%	   -­‐	   21.3	  DeTC	  14.5	  MTC	   Benekli	  et	  al.	  [80]	  
DeTC: Dedifferentiated Thyroid Cancer; MTC: Medullary Thyroid Cancer; ATC: Anaplastic Thyroid Cancer 
PR: Partial Response; SD: Stable Disease; PD: Progressive Disease; PFS: Progression Free Survival 
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Table II. Sorafenib undesirable effects. 
 
Classification 
(system or organ) 





(≥ 1/100, < 1/10) 
Uncommon 
(≥ 1/1000, < 1/100) 
Rare 












 Hypertensive crisis  
Cardiac diseases  Congestive heart 
failure, myocardial 
ischaemia 
 QT prolungation 
Respiratory tract and 
mediastinic diseases 





























 Erectile dysfunction Gynecomastia  
Neurological 
Diseases 










 Arthralgia, myalgia  Rhabdomyolysis 
Immune system 
disorders 
  Hypersensivity (skin 




Skin Rash, alopecia, hand-








Infections   Infection 
Folliculitis 
 
Psychiatric disorder  Depression   
Other diseases  Fatigue, pain (mouth, 
abdomen, bone, 
oncologic), headache 




Laboratory exams Increasing levels of 
amylase and lipase 
Weight loss, increasing 
levels of hepatic 
enzyme 
Alteration of INR 
value 
 
INR=International Normalized Ratio 
 
 
